Testing two drugs for hard-to-treat triple-negative breast and ovarian cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Skin, Women’s health & pregnancy clinical trials.
This Phase 1 trial tests ribociclib plus belinostat in people with metastatic triple-negative breast cancer or recurrent ovarian cancer. It also looks at your tumor’s genetics (from a fresh biopsy) to see who might respond better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 or older.
- Your cancer is triple-negative breast cancer (ER and PR 1% or less, and HER2 negative) OR recurrent serous ovarian cancer that can’t be removed (unresectable).
- Your cancer has measurable tumors you can track, and you have at least one place doctors can safely biopsy (up to 3 lesions).
- You can take pills by mouth and you’re well enough to do daily activities (ECOG 0–2).
- Your blood counts and key organs (kidneys, liver) meet lab thresholds for safe treatment.
- You must be able to avoid pregnancy during the study and for 6 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study compares two combinations of hormone-blocking drugs plus an anti-cancer targeted pill to see which works better for hormone-receptor positive, HER2-negative metastatic breast cancer. It may help by finding a more effective treatment plan when the cancer has spread.
This study tests how well and how safely different combinations of cancer drugs work for people with metastatic or inoperable locally advanced breast cancer. It may help by finding a better treatment option and collecting information to guide future care.
This trial tests a new approach: starting with a targeted pill (ribociclib) plus hormone therapy (an aromatase inhibitor), instead of immediate chemotherapy, for women with a specific type of breast cancer (ER low-positive, HER2-negative) that is growing quickly. If eligible, you would not have received any prior treatment for your advanced cancer.
This trial tests an oral “CDK” medicine in people with triple-negative breast cancer who are about to receive standard treatment. It’s designed to help researchers see whether the drug can control or improve the cancer early, using planned biopsies and scans.
This study tests a new version of the hormone therapy letrozole (Letrozole SIE) compared to the standard letrozole (Femara®), both given together with a targeted therapy called ribociclib. It is for postmenopausal women with HR-positive, HER2-negative breast cancer that has spread to other parts of the body and has not yet been treated for advanced disease.
This trial looks at how well ribociclib works and why it may stop working over time in people with advanced, hormone-receptor–positive, HER2-negative breast cancer. It also analyzes blood and tissue samples to help researchers understand resistance patterns and improve future treatment decisions.
Hear when a new Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.